Skip to Main content Skip to Navigation
Journal articles

Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant

Abstract : The impact of pre-transplant anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and/or their donors is reported here, showing that the persistence of anti-SARS-CoV-2 antibodies can be detected in almost all patients, whatever the type of vaccine used, and up to 9 months post transplant. Also, an anti-SARS-CoV-2 spike glycoprotein CD3+ T-cell response could be detected in six (35%) of 17 evaluable patients. This study provides a rationale to consider anti-SARS-CoV-2 vaccination of both recipients and donors before Allo-HSCT.
Complete list of metadata
Contributor : Jocelyn Ollier Connect in order to contact the contributor
Submitted on : Friday, February 18, 2022 - 5:04:54 PM
Last modification on : Wednesday, April 27, 2022 - 4:59:34 AM
Long-term archiving on: : Thursday, May 19, 2022 - 7:48:09 PM


2022 (eJHaem) Anti‐SARS‐Co...
Publication funded by an institution



Maxime Jullien, Marianne Coste‐burel, Beatrice Clemenceau, Valentin Letailleur, Thierry Guillaume, et al.. Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant. eJHaem, 2022, ahead of print. ⟨10.1002/jha2.398⟩. ⟨inserm-03580755⟩



Record views


Files downloads